Abstract |
Increased activation of CD95/Fas by Fas ligand in viral hepatitis and autoimmunity is involved in pathogenesis of fulminant hepatitis and liver failure. We designed a bile-acid phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide (UDCA-LPE with LPE containing oleate at the sn-1) as a hepatoprotectant that was shown to protect against fulminant hepatitis induced by endotoxin. We herein further assessed the ability of UDCA-LPE to prevent death receptor CD95/Fas-induced fulminant hepatitis. C57BL/6 mice were intravenously administered with CD95/Fas agonistic monoclonal antibody (Jo-2) with or without 1 h pretreatment with 50 mg/kg UDCA-LPE. Jo-2 administration caused massive hepatocyte damage as seen by histology, and this was associated with a significant decrease in hepatic phosphatidylcholine (PC), lysoPC, and lysophosphatidylethanolamine levels. By histology, UDCA-LPE pretreatment improved hepatocyte damage and restored the loss of these phospholipids in part by a mechanism involving an inhibition of cytosolic phospholipaseA2 expression. Accordingly, Jo-2 treatment increased hepatic expression of cleaved caspase 8, caspase 3, and poly (ADP-Ribose) polymerase-1, and on the other hand decreased that of anti-apoptotic cellular FLICE-inhibitory protein. UDCA-LPE pretreatment was able to reverse all these changes. Moreover, UDCA-LPE attenuated inflammatory response by lowering the levels of Jo-2-induced proinflammatory cytokines TNF-α, IL-6, and IL-1β in liver and serum. UDCA-LPE was also able to decrease the levels of stimulated Th1/Th17 cytokines in Jo-2-primed isolated splenocytes. Taken together, UDCA-LPE exhibited potent anti-inflammatory effects against CD95/Fas-induced fulminant hepatitis.
|
Authors | Tanyarath Utaipan, Ann-Christin Otto, Hongying Gan-Schreier, Warangkana Chunglok, Anita Pathil, Wolfgang Stremmel, Walee Chamulitrat |
Journal | Shock (Augusta, Ga.)
(Shock)
Vol. 48
Issue 2
Pg. 251-259
(08 2017)
ISSN: 1540-0514 [Electronic] United States |
PMID | 28060213
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Inflammatory Agents
- Fas Ligand Protein
- Fasl protein, mouse
- Lysophospholipids
- fas Receptor
- ursodeoxycholyl lysophosphatidylethanolamide
- Ursodeoxycholic Acid
|
Topics |
- Animals
- Anti-Inflammatory Agents
(pharmacology)
- Fas Ligand Protein
(adverse effects, pharmacology)
- Gene Expression Regulation
(drug effects)
- Liver
(metabolism, pathology)
- Liver Failure, Acute
(chemically induced, drug therapy, metabolism, pathology)
- Lysophospholipids
(pharmacokinetics)
- Male
- Mice
- Ursodeoxycholic Acid
(analogs & derivatives, pharmacokinetics)
- fas Receptor
(metabolism)
|